STAAR Surgical Company announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for its EVO/EVO+ Visian Implantable Collamer Lenses (EVO ICL), now allowing use for patients aged 21 to 60 years old. The lenses were previously approved for patients aged 21 to 45. This expansion follows the publication of three-year FDA clinical trial safety data supporting the long-term safety profile of EVO ICL.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202602171601BIZWIRE_USPR_____20260217_BW181103) on February 17, 2026, and is solely responsible for the information contained therein.
Comments